EUVIMEDOdkrijte EUVIMED
Open access · CC BY 4.0

The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions

Zhao Cheng iD, Darren P Ennis iD, Bingxin Lu iD, Hasan B Mirza iD, Chishimba Sokota, Baljeet Kaur iD, Naveena Singh, Olivia Le Saux, Giorgia Russo iD, Gaia Giannone iD, Laura A Tookman, Jonathan Krell and 3 more

The Journal of Pathology · 2024-09 · 264 (1) · 42-54

DOI: 10.1002/path.6322 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2024-07-02. Written by Zhao Cheng and 14 co-authors. Institution: Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK. Major MEDLINE topics: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Fallopian Tube Neoplasms, Tumor Suppressor Protein p53. Cited 22 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre, La Ligue contre le Cancer, La Fondation Nuovo-Soldati.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Ovarian high‐grade serous carcinoma (HGSC) originates in the fallopian tube, with secretory cells carrying a TP53 mutation, known as p53 signatures, identified as potential precursors. p53 signatures evolve into serous tubal intraepithelial carcinoma (STIC) lesions, which in turn progress into invasive HGSC, which readily spreads to the ovary and disseminates around the peritoneal cavity. We recently investigated the genomic landscape of early‐ and late‐stage HGSC and found higher ploidy in late‐stage (median 3.1) than early‐stage (median 2.0) samples. Here, to explore whether the high ploidy and possible whole‐genome duplication (WGD) observed in late‐stage disease were determined early in the evolution of HGSC, we analysed archival formalin‐fixed paraffin‐embedded (FFPE) samples from five HGSC patients. p53 signatures and STIC lesions were laser‐capture microdissected and sequenced using shallow whole‐genome sequencing (sWGS), while invasive ovarian/fallopian tube and metastatic carcinoma samples underwent macrodissection and were profiled using both sWGS and targeted next‐generation sequencing. Results showed highly similar patterns of global copy number change between STIC lesions and invasive carcinoma samples within each patient. Ploidy changes were evident in STIC lesions, but not p53 signatures, and there was a strong correlation between ploidy in STIC lesions and invasive ovarian/fallopian tube and metastatic samples in each patient. The reconstruction of sample phylogeny for each patient from relative copy number indicated that high ploidy, when present, occurred early in the evolution of HGSC, which was further validated by copy number signatures in ovarian and metastatic tumours. These findings suggest that aberrant ploidy, suggestive of WGD, arises early in HGSC and is detected in STIC lesions, implying that the trajectory of HGSC may be determined at the earliest stages of tumour development. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousFallopian Tube NeoplasmsTumor Suppressor Protein p53HumansFemaleCarcinoma in SituNeoplasm GradingDNA Copy Number VariationsMutationGenomicsWhole Genome SequencingPloidiesMiddle AgedBiomarkers, TumorDisease Progression

Author keywords

STICevolutionhigh‐grade serous carcinomawhole‐genome duplication

Substances

Tumor Suppressor Protein p53TP53 protein, humanBiomarkers, Tumor

Authors and institutions

  • Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
  • Department of Cell and Developmental Biology, University College London, London, UK.
  • Department of Cellular Pathology, Imperial College Healthcare NHS Trust, London, UK.
  • Department of Pathology, Barts Healthcare NHS Trust, London, UK.

ORCID profiles: Zhao Cheng, Darren P Ennis, Bingxin Lu, Hasan B Mirza, Baljeet Kaur, Giorgia Russo, Gaia Giannone, Chris Barnes, Iain A McNeish

Funding

  • National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre
  • La Ligue contre le Cancer
  • La Fondation Nuovo-Soldati
  • Canceropole Lyon Auvergne Rhone-Alpes
  • Cancer Research UK
  • National Institute for Health and Care Research

Cite

APA

Cheng, Z., Ennis, D. P., Lu, B., Mirza, H. B., Sokota, C., Kaur, B., Singh, N., Le Saux, O., Russo, G., Giannone, G., Tookman, L. A., Krell, J., Barnes, C., McDermott, J., & McNeish, I. A. (2024). The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions. The Journal of Pathology, 264(1), 42-54. https://doi.org/10.1002/path.6322

Vancouver

Cheng Z, Ennis DP, Lu B, Mirza HB, Sokota C, Kaur B, et al. The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions. The Journal of Pathology. 2024;264(1):42-54. doi:10.1002/path.6322

BibTeX
@article{Cheng2024,
  author = {Cheng, Zhao and Ennis, Darren P and Lu, Bingxin and Mirza, Hasan B and Sokota, Chishimba and Kaur, Baljeet and Singh, Naveena and Le Saux, Olivia and Russo, Giorgia and Giannone, Gaia and Tookman, Laura A and Krell, Jonathan and Barnes, Chris and McDermott, Jackie and McNeish, Iain A},
  title = {The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions},
  journal = {The Journal of Pathology},
  year = {2024},
  volume = {264},
  number = {1},
  pages = {42--54},
  doi = {10.1002/path.6322}
}
Start for free →